Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Rx Comparative Effectiveness Research Funds Included In HHS Approps Bill

  • News

Executive Summary

Funding for prescription drug comparative effectiveness research is included in the HHS fiscal year 2005 appropriations bill reported to the full Senate Sept. 15

You may also be interested in...



FY 2006 appropriation for effectiveness research

House/Labor, HHS & Education Subcommittee mark for fiscal 2006 appropriations budgets $15 mil. for AHRQ to perform comparative effectiveness research. AHRQ received $15 mil. for the program in FY 2005 (1"The Pink Sheet" Sept. 20, 2004, p. 14)...

FY 2006 appropriation for effectiveness research

House/Labor, HHS & Education Subcommittee mark for fiscal 2006 appropriations budgets $15 mil. for AHRQ to perform comparative effectiveness research. AHRQ received $15 mil. for the program in FY 2005 (1"The Pink Sheet" Sept. 20, 2004, p. 14)...

Rx Comparative Effectiveness Research Funding In Doubt

Prescription drug comparative effectiveness research funding is not in the fiscal year 2005 HHS approps bill reported out of the House Appropriations Committee July 14

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS044693

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By